Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3—A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.
The DOI matches its Crossref record.
Abstract
445 Background: The FIRE-3 study (AIO KRK-0306) was designed as a randomized multicenter trial to compare the efficacy of FOLFIRI plus cetuximab (cet) to FOLFIRI plus bevacizumab (bev) as first-line treatment in KRAS WT mCRC patients. FOLFIRI plus cet as first-line treatment of KRAS WT mCRC patients resulted in comparable overall response rates (ORR) and progression free survival (PFS) when compared to FOLFIRI plus bev. Overall survival (OS) was significantly longer in the FOLFIRI plus cet arm. Methods: In a preplanned analysis, the effect of mutations within the EGFR dependent pathway were investigated. Next to mutations within KRAS (exon 2, 3, 4), NRAS (exon 2, 3, 4) and BRAF (V600E), mutations within PIK3CA (exon 9 and 20) and Akt were investigated and their impact on ORR, PFS and OS within the FIRE-3 population was evaluated. The analysis of all mutations was carried out employing pyrosequencing. Results: The ITT population consisted of 592 KRAS WT (exon 2) patients. The current analysis includes 488 cases (82.4%) with tumor tissue available. In 407 pts sequencing of all RAS mutations was possible. The ORR within the WT RAS patient group was higher in the FOLFIRI plus cet arm (65.5% vs 59.6%; Fisher´s p: 0.157). HRs (cet; bev) for pts with WT RASwere 0.93 (95% CI, 0.74-1.17; p = 0.54) for PFS and 0.70 (95% CI, 0.53-0.92; p = 0.01) for OS. PIK3CA mutation did not influence PFS nor OS when compared to the RAS wt population. Conclusions: ORR and OS were increased in patients with cet plus FOLFIRI as compared to bev plus FOLFIRI in patients without RAS mutations. Exclusion of patients with RAS mutations identifies a population which is more likely to benefit from cetuximab. Clinical trial information: NCT00433927.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Self-citationVan Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167
Yoshino, T., Arnold, D., Taniguchi, H., Pentheroudakis, G., Yamazaki, K., Xu, R.-H., Kim, T. W., Ismail, F., Tan, I. B., Yeh, K.-H., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx738 · Cited by 573
Sorich, M. J., Wiese, M. D., Rowland, A., Kichenadasse, G., McKinnon, R. A., & Karapetis, C. S. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu378 · Cited by 540
Pietrantonio, F., Petrelli, F., Coinu, A., Di Bartolomeo, M., Borgonovo, K., Maggi, C., Cabiddu, M., Iacovelli, R., Bossi, I., Lonati, V., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.01.054 · Cited by 486
“Stintzing/2014 [23] Phase III/342/100 FOLFIRI + C or B 1st NA 13.”
BackgroundMethodPrice, T. J., Peeters, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Suresh, A. S., Thomas, A., Tjulandin, S., Zhang, K., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70118-4 · Cited by 473
Biomarker-guided therapy for colorectal cancer: strength in complexity
Sveen, A., Kopetz, S., & Lothe, R. A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0241-1 · Cited by 320
BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives
Sanz-Garcia, E., Argiles, G., Elez, E., & Tabernero, J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx401 · Cited by 302
Peeters, M., Kafatos, G., Taylor, A., Gastanaga, V. M., Oliner, K. S., Hechmati, G., Terwey, J.-H., & van Krieken, J. H. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.05.017 · Cited by 163
Ciardiello, F., Normanno, N., Maiello, E., Martinelli, E., Troiani, T., Pisconti, S., Giuliani, F., Barone, C., Cartenì, G., Rachiglio, A. M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu230 · Cited by 116
Association between KRAS mutation and lung metastasis in advanced colorectal cancer
Pereira, A. A. L., Rego, J. F. M., Morris, V, Overman, M. J., Eng, C., Garrett, C. R., Boutin, A. T., Ferrarotto, R., Lee, M., Jiang, Z.-Q., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.619 · Cited by 94
Metadata
- Authors
- Stintzing, S., Jung, A., Rossius, L., Modest, D. P., Fischer von Weikersthal, L., Decker, T., Kiani, A., Al-Batran, S.-E., Vehling-Kaiser, U., Heintges, T., Moehler, M., Scheithauer, W., Kirchner, T., & Heinemann, V.
- Venue
- Journal of Clinical Oncology
- Published
- 2014-01-20
- Volume
- 32
- Issue
- 3_suppl
- Pages
- 445-445
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2486490809
- Cited by
- 97
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.